AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
AFT Leaves X Over AI-Generated Images of Minors 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, securing wins in the "Biologics – Global" category. It also received accolades for “Best Scientific Expertise,” “Best Seamless Delivery Across Phases,” and “Best Innovative Approach to Technology and Process Execution,” making it the most celebrated company at the event. This marks the company’s eighth consecutive win, highlighting its consistent excellence in biologics development and manufacturing.
The awards, presented by Outsourced Pharma and Life Science Leader, evaluated 210 CDMOs across biologics, small molecule APIs, and cell & gene therapies in global, North American, and international regions through third-party research.
WuXi Biologics continues to revolutionize the biologics industry by shortening monoclonal antibody development timelines from DNA to IND to just nine months, with a recent autoimmune project completed in six months. Leveraging single-use technology (SUT), the company scaled manufacturing from 4,000L to 16,000L globally with a 99% success rate between 2022 and 2024—achieving cost parity with traditional stainless steel systems. The firm also maintains a 100% success rate in pre-approval inspections, with over 40 global regulatory audits, including 22 from the FDA and EMA.
CEO Dr. Chris Chen said, “This award reflects the trust of our partners and the dedication of our team. We’re committed to accelerating the delivery of life-saving therapies worldwide.”
With over 12,000 employees across China, the U.S., Ireland, Germany, and Singapore, WuXi Biologics supports 817 client projects, including 21 in commercial manufacturing as of December 2024. The company’s commitment to sustainability and green CRDMO solutions reinforces its leadership in advancing global healthcare.
